Introduction {#Sec1}
============

Premix insulin analogs are well established as a treatment for type 2 diabetes (T2D). However, there is a lack of clear practical guidance to help clinicians choose an initial regimen. A number of overarching criteria need to be taken into consideration. These include the need to target both fasting plasma glucose (FPG) and postprandial glucose (PPG) to achieve optimal glycemic control \[[@CR1]\]; the importance of individualizing therapy; and the need to intensify the insulin regimen to compensate for the progressive nature of diabetes. Furthermore, currently available literature contains almost no information on how to switch patients from basal--bolus to premix therapy when patients fail to cope with the more intensive insulin regimen. With the growing prevalence of T2D, the responsibility for the care of patients is increasingly moving to general practitioners (GPs), many of whom would welcome clear and straightforward guidance on insulin management.

With this in mind, the authors of this report---an independent expert panel of endocrinologists and GPs with a special interest in diabetes, all based in Australia and New Zealand---met in Sydney in February 2014. The panel's objective was to formulate guidance on how to undertake the following activities: initiating therapy with premix insulin analogs; recognizing when patients need intensification of their insulin therapy; and switching from basal--bolus to premix insulin analog therapy when appropriate.

Methods {#Sec2}
=======

The panel chose to focus on the premix insulin analog formulations widely available in Australasia as of February 2014: biphasic insulin aspart, containing 30% soluble insulin aspart and 70% protamine-crystallized insulin aspart (BIAsp 30), and biphasic insulin lispro, containing 25% soluble insulin lispro and 75% protamine-crystallized insulin lispro (lispro mix 25). In this document, the term 'premix insulin analogs' covers both BIAsp 30 and lispro mix 25; the term 'premix insulins' is used to cover both human and analog premixes when citing references where the term was used in this way.

The panel's intention is that the guidance should be specific and detailed enough to be useful in primary care as well as for specialists. As far as possible, the recommendations are evidence based. However, since the evidence on approaches for treatment is incomplete, some of the recommendations are given by the writing group as a consensus and indicated as such.

The guidance in this statement covers T2D only and does not include type 1 diabetes, gestational diabetes, latent autoimmune diabetes of adults, patients in end-stage renal disease, or steroid-induced diabetes. The recommendations have been formulated for Australia and New Zealand, but should be useful globally. No representations are made about local prescribing regulations or funding status in specific countries. Currently, evidence is not available to make recommendations concerning new combination insulins, such as insulin degludec/insulin aspart, or other new combination regimens such as insulin--incretin combinations. This guidance will, therefore, be subject to change as new information becomes available.

It should be noted that the guidance provides recommendations that are intended to be helpful, and that none of the suggested actions are mandatory.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec3}
=======

Current Guidelines {#Sec4}
------------------

Previously, guidelines on the management of T2D prescribed fixed glycemic targets for all patients. More recent guidance from bodies such as the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the International Diabetes Federation (IDF) have formalized the concept of 'patient-centered care', which includes setting targets in line with individual patients' needs, preferences, and tolerances \[[@CR2], [@CR3]\]. This concept is now increasingly accepted. Glycemic targets that will be appropriate for most patients are still suggested, as shown in Table [1](#Tab1){ref-type="table"}, but with the understanding that individualization of targets is imperative.Table 1Glycemic targets applicable to most patients according to existing guidelinesItemADA/EASD \[[@CR2]\]\
ADA \[[@CR4]\]IDF \[[@CR1], [@CR3]\]American Association of Clinical Endocrinologists \[[@CR5]\]Diabetes Australia and the National Health and Medical Research Council \[[@CR6]\]Royal Australian College of General Practitioners \[[@CR7]\]New Zealand Guidelines Group \[[@CR8]\]HbA1c, general (%)/(mmol/mol)\<7.0/\<53\<7.0/\<53\<7.0/\<53\<7.0/\<53≤7.0/≤536.9--7.1^a^/50--55FPG (mmol/L)/(mg/dL)\<7.2/\<1306.5/115Suggests adding 1 unit of insulin if fasting blood glucose 5.6--7.7/100--1396.0--8.0/108--1446.0--8.0/108--144Not stated (ranges are given for titration of insulin)PPG (mmol/L)/(mg/dL)\<10.0/\<1809.0/16010.0/1806.0--10.0/108--1808.0--10.0/144--180Not statedTime for PPG measurementNot specified (2 h for diagnosis of diabetes)1--2 h2 h2 hNot statedNot statedComments regarding the use of premix insulinPremix insulin is suggested as a possibly more convenient but less adaptable method of intensifying insulin therapyPremix insulin (OD or BID) may be used for insulin initiation \[[@CR3]\]Prefers basal insulin as initial therapy, and basal--bolus regimens for intensification, but recognizes that premix insulins are simpler and may be better for some patientsInsulin can be initiated as basal therapy or with premix insulinsInsulin can be initiated as basal therapy or with premix insulins, usually in combination with oral antidiabetic medicationsPremix insulin can be considered if PPG levels are elevated and HbA1c target has not been metTargets should always be set individually according to patient factors*ADA* American Diabetes Association, *BID* twice daily, *EASD* European Association for the Study of Diabetes, *FPG* fasting plasma glucose, *OD* once daily, *PPG* postprandial glucose^a^Percentage values have been calculated and added

Choosing an appropriate insulin type and regimen should also be based on specific patient attributes \[[@CR5]\], rather than taking a 'one-size-fits-all' approach, and many guidelines now recognize both basal and premix insulin as options for initiating/intensifying insulin therapy in T2D (Table [1](#Tab1){ref-type="table"}). Indeed, the loss of the first-phase insulin release is one of the earliest detectable defects of beta-cell function in individuals destined to develop T2D \[[@CR9]\]. The resultant postprandial hyperglycemia has been associated with an increased risk of harmful outcomes such as macrovascular disease, retinopathy, and cancer \[[@CR1]\]. Unlike basal insulin, premix insulin targets both FPG and PPG, which is essential for addressing this glycemic defect and achieving optimal glycemic control. With this in mind, it is important to determine the glycemic defect through blood glucose monitoring before choosing an insulin initiation regimen.

It is important to note that the ADA/EASD statement emphasizes the progressive nature of T2D and the likelihood that intensification of therapy will be needed as beta-cell function deteriorates \[[@CR2]\].

Evidence Base for Premix Insulin Analogs in Initiation, Intensification, and Switching {#Sec5}
--------------------------------------------------------------------------------------

### Initiation of Insulin: Premix Insulin Analogs Vs. Basal Analogs {#Sec6}

An extensive clinical dataset, based on numerous randomized clinical trials and real-life observational studies, supports the efficacy and good safety profiles of BIAsp 30 and lispro mix 25 in the initiation and intensification of insulin therapy; these data have been reviewed \[[@CR10], [@CR11]\].

A small number of trials compared the use of either premix insulin analogs or basal insulin analogs for insulin initiation. Systematic reviews of the available evidence \[[@CR12]--[@CR14]\] suggest that treatment with premix insulin analogs as first-line insulin therapy results in significantly better overall glycemic control, but slightly greater risk of hypoglycemia and weight gain, compared with basal insulin. A more recent review of eight trials comparing insulin initiation with either premix analogs or basal analogs showed greater glycated hemoglobin (HbA1c) reductions, weight gain, and number of hypoglycemic episodes with the premix analogs (significance of differences not reported) \[[@CR15]\]. The authors suggested that factors that are not addressed in clinical trials, such as complexity of regimens and the need for titration, may influence outcomes.

The most recently published trial comparing BIAsp 30 once daily (OD) with a basal analog (insulin glargine OD) for insulin initiation in T2D was OnceMix (ClinicalTrials.gov number, NCT00469092) \[[@CR16]\]. The estimated mean reduction in HbA1c was −1.41% (15 mmol/mol) with BIAsp 30 and −1.25% (14 mmol/mol) with insulin glargine (difference \[95% confidence interval\]: −0.16% \[−0.30; −0.02\] or −2 mmol/mol \[−3; −0.2\]; *P* = 0.029). There was a significant improvement in PPG with BIAsp 30 after dinner and before bed when compared with insulin glargine, with differences of −0.52 mmol/L (*P* = 0.04) and −0.78 mmol/L (*P* \< 0.01), respectively. The risk of hypoglycemia, while low in both groups, was slightly higher with BIAsp 30 for overall hypoglycemia (6.5 vs. 4.8 episodes/patient-year; *P* = 0.034) and nocturnal hypoglycemia (1.1 vs. 0.5 episodes/patient-year; *P* = 0.003). However, the proportion of patients who achieved an HbA1c level \<7% with no hypoglycemia was the same in the two groups (20.0% with BIAsp 30 and 19.4% with insulin glargine). Weight change did not differ between the groups.

DURABLE (ClinicalTrials.gov number, NCT00279201) compared lispro mix 25 twice daily (BID) with insulin glargine OD in previously insulin-naïve patients \[[@CR17]\]. Treatment with lispro mix 25 resulted in slightly greater reductions in HbA1c at 24 weeks: −1.8 ± 1.3% (−20 ± 14 mmol/mol) vs. −1.7 ± 1.3% (−19 ± 14 mmol/mol) (*P* = 0.005). The lispro mix group also had more weight gain: 3.6 ± 4.0 vs. 2.5 ± 4.0 kg (*P* \< 0.0001) and higher rates of overall hypoglycemia (28.0 ± 41.6 vs. 23.1 ± 40.7 episodes/patient-year; *P* = 0.007), but lower rates of nocturnal hypoglycemia (8.9 ± 19.3 vs. 11.4 ± 25.3 episodes/patient-year; *P* = 0.009). A follow-up study over 24 months showed durability of glycemic control was longer with lispro mix 25 \[[@CR18]\].

### Intensification of Insulin: Premix Insulin Analogs vs. Basal-Plus or Basal--Bolus Regimens {#Sec7}

A meta-analysis published in 2011 \[[@CR19]\] compared premix insulin analogs with basal--bolus therapy based on three trials: PREFER (ClinicalTrials.gov number, NCT00605020), which compared BIAsp 30 BID with insulin detemir plus insulin aspart at mealtimes \[[@CR20]\]; a study comparing lispro mix 50 (containing 50% soluble insulin lispro and 50% protamine-crystallized insulin lispro) three times daily (TID) with insulin glargine plus insulin lispro TID \[[@CR21]\]; and the 3-year follow-up of the 4T study, comparing BIAsp 30 BID, insulin aspart TID, or insulin detemir OD or BID as initial regimens \[[@CR22]\]. In 4T, if glycemic control was inadequate, lunchtime insulin aspart was added to BIAsp 30 BID, bedtime basal insulin was added to insulin aspart TID, and insulin aspart TID was added to basal insulin. Most of the patients in the prandial and basal groups switched to basal--bolus therapy \[[@CR23]\]. Based on these three trials, the authors concluded that patients treated with a basal--bolus regimen had a higher chance of reaching their HbA1c goal (odds ratio \[95% confidence interval\]: 1.75 \[1.11; 2.77\]), with no difference in incidence of hypoglycemia or weight gain between the two regimens \[[@CR19]\]. The results have to be interpreted cautiously, as the trial populations included insulin-naïve patients as well as patients already receiving basal insulin at the start of the treatment periods.

Further studies have been published since 2011, some only as abstracts at the time of the panel meeting. In PARADIGM (ClinicalTrials.gov number, NCT00548808), lispro mix 25 OD, BID, or TID, as needed, was compared with insulin glargine plus one, two, or three injections of insulin lispro, as needed. Glycemic control, weight change, hypoglycemia, the number of injections, and the increase in insulin dose were all similar between groups \[[@CR24]\]. A phase IV study, GALAPAGOS (ClinicalTrials.gov number, NCT01121835), compared BIAsp 30 OD or BID with insulin glargine OD plus insulin glulisine OD if needed ('basal-plus'). With BIAsp 30, 52.6% of patients achieved HbA1c \<7% compared with 43.2% of those receiving basal-plus (*P* = 0.005). However, rates of hypoglycemia were higher with BIAsp 30: 2.9 vs. 1.2 episodes/patient-year for overall hypoglycemia, and 1.0 vs. 0.4 episodes/patient-year for nocturnal episodes (both *P* \< 0.01) \[[@CR25]\]. Finally, the LanScape study (ClinicalTrials.gov number, NCT00965549) compared BIAsp 30 OD with insulin glargine OD plus insulin glulisine OD at the main meal \[[@CR26]\]. Reduction in HbA1c did not differ between the two regimens. There was no difference between overall hypoglycemia rates, but there were fewer nocturnal events with BIAsp 30 OD (3.6 vs. 5.7 events/patient-year; *P* = 0.02).

Factors influencing the choice of either premix insulin analogs or basal--bolus regimens for intensification in a primary care setting have recently been reviewed \[[@CR27]\]. The authors of this study found inconclusive evidence and a lack of direct comparisons, and pointed out that clinical trials do not necessarily reflect real-world patients. In their view, GPs know their patients well and are in a good position to select the appropriate regimen for their patients (e.g., premix or basal-plus/basal--bolus therapy). However, GPs need sufficient time and support to accomplish this task.

### Switching from Basal--Bolus to Premix Therapy {#Sec8}

Switching from a basal--bolus insulin regimen to premix insulin analogs is a relatively uncommon scenario. While basal--bolus therapy is considered the 'gold standard' for patients with advanced T2D, two groups of patients may need to switch to premix insulin analogs either BID or TID. These are patients who are unable or unwilling to cope with the complexity of a basal--bolus regimen, and patients who commence treatment with basal--bolus therapy in hospital (as occurs routinely in Australia, in accordance with guidelines from the Australian Diabetes Society \[[@CR28]\]) and no longer require such an intensive regimen following discharge.

There is minimal published evidence on how to make this switch. Some evidence is available from a subgroup of the observational A~1~chieve study (ClinicalTrials.gov number, NCT00869908), in which patients who were inadequately controlled on antidiabetic medication started or were switched to either BIAsp 30, insulin aspart, or insulin detemir \[[@CR29]\]. The subgroup consisted of patients who were inadequately controlled on basal--bolus therapy using insulin glargine (*n* = 240) or neutral protamine Hagedorn insulin (*n* = 784) and who switched to BIAsp 30, mostly BID \[[@CR30]\]. At 24 weeks, mean HbA1c decreased by approximately 2.5% (27 mmol/mol) and 1.9% (21 mmol/mol), respectively (*P* \< 0.001 in both groups). The proportions reporting overall, major, or nocturnal hypoglycemia were significantly reduced (*P* \< 0.05 in all cohorts) after switching to BIAsp 30. While this was not a randomized trial, the results do suggest that selected patients inadequately controlled on a basal--bolus regimen can benefit by switching to a premix insulin analog. The authors speculate that the improved results may have arisen from better therapy adherence due to the simpler regimen with BIAsp 30.

To our knowledge, the only previously published recommendations for switching from basal--bolus therapy to premix insulin analogs were included in Turkish guidelines, not available in English, on the use of BIAsp 30 in T2D \[[@CR31]\]. These suggested that patients should be switched to BIAsp 30 BID or TID in preference to OD.

Conclusions from the Available Evidence {#Sec9}
---------------------------------------

The results from the trials in both initiation and intensification of insulin show that, in general, a better HbA1c reduction was accompanied by a higher rate of hypoglycemia, and both arms were accompanied by weight gain. No single insulin or regimen was best on all endpoints. Furthermore, while the differences may have reached statistical significance, they were often of limited clinical relevance. It is clear that improved glycemic control can be expected, irrespective of which regimen is used. Thus, individual patient factors and preferences become more important, and the focus must be on selecting the regimen that is best for the particular patient---including any features likely to aid adherence.

It is important to choose a regimen to which patients are likely to adhere. Non-adherence to insulin therapy has been linked with unfavorable outcomes \[[@CR32], [@CR33]\]; conversely, treatment persistence has been associated with improved clinical outcomes \[[@CR34]\]. A full discussion of adherence issues is outside the scope of this guidance. However, studies of adherence to antidiabetic therapy in general (not necessarily insulin) have shown that factors affecting adherence include the patient's comprehension of the treatment regimen and its benefits, adverse effects, medication costs, regimen complexity, and frequency and timing of dosing \[[@CR35], [@CR36]\]. One study showed that the main predictor of adherence was patients' ratings of the burden of therapy, and that the patients' perceived burden of therapy increased as the number of injections increased \[[@CR37]\].

Very little evidence is available on the scenario in which patients need to switch from basal--bolus to premix insulin therapy.

Recommendations {#Sec10}
===============

Initiating Insulin Therapy with Premix Insulin Analogs in Primary Care {#Sec11}
----------------------------------------------------------------------

### Preparing Patients for Insulin Therapy {#Sec12}

Patients may fear initiating insulin for many reasons: fear of hypoglycemia or weight gain; concern that insulin therapy indicates that they are heading towards severe complications such as blindness, limb amputation, or kidney failure; resistance to the need for monitoring blood glucose; or a belief that starting insulin indicates a failure on their part. It is important to allay these fears \[[@CR38], [@CR39]\]. It is also important to select the right HbA1c target for the individual patients. If the target is set too low, patients may omit insulin to avoid hypoglycemia, at the expense of their glycemic control.

### Choosing the Most Appropriate Insulin Regimen for the Patient {#Sec13}

When choosing an insulin regimen for initiation, it is imperative to bear in mind the long-term progressive nature of T2D and the likely need for intensification. The patient's ability to cope with intensification should influence the choice of initiation regimen.

Figure [1](#Fig1){ref-type="fig"} summarizes patient characteristics that may help determine a preference for either basal insulin or premix insulin analogs. Choose the regimen that provides the best match overall to the characteristics described. Age is not shown in Fig. [1](#Fig1){ref-type="fig"}, as function and degree of frailty are more important than chronological age. If life expectancy is short, the probability of future insulin intensification is less important.Fig. 1Patient factors to consider when deciding whether to use premix insulin analog or basal insulin for initiation (based on consensus). The figure shows both immediately applicable factors and other factors that will determine whether future intensification should be with basal--bolus or premix insulin analog therapy

### Dosing, Titration, and Monitoring {#Sec14}

See "[Box 1](#Sec15){ref-type="sec"}" for guidance on dose and titration when initiating insulin with premix insulin analogs.

#### Box 1: Dosing/titration guidelines for initiating insulin with premix insulin analogs OD (based on consensus) {#Sec15}

When choosing an insulin dose, and for dose titration, err on the side of safety and convenience.Initiate with premix insulin analog OD, immediately before or soon after the start of the meal with the highest prandial load (usually the evening meal).Initiate with a dose of 10--12 units and titrate.[1](#Fn1){ref-type="fn"}Increase by 2 units once or twice a week until the patient reaches target \[aim for \<7 mmol/L (\<126 mg/dL), but no values \<4 mmol/L (\<72 mg/dL) based on the lowest premeal glucose level\] or experiences hypoglycemia (see dose adjustment table). Dose titration can be halted when self-monitored blood glucose levels consistently fall within the target.If blood glucose \<4 mmol/L (\<72 mg/dL) or hypoglycemia occurs, down-titrate by 2 units. If hypoglycemia persists, the patient should review with their doctor or nurse.Dose adjustmentLowest premeal blood glucose levelAdjustment for the next dose≥7.0 mmol/L (≥126 mg/dL)+2 units4.1--6.9 mmol/L (73--124 mg/dL)0 units≤4.0 mmol/L (≤72 mg/dL)−2 units

When titrating, use the lowest of the three most recent self-monitored blood glucose (SMBG) values (premeal, at least 8 h after last injection) to decide whether to adjust the dose. If the dose reaches 40--50 units, consider splitting it by adding another injection.

Schedule regular clinical review. Review therapy if SMBG is not near target despite increasing dose of insulin (\>1 unit/kg per day). Factors to review include patient's diet, compliance with insulin, injection technique, and injection sites.

### Use of Other Glucose-Lowering Drugs {#Sec16}

See "[Box 2](#Sec17){ref-type="sec"}" for guidance on the use of other glucose-lowering drugs when initiating insulin with premix insulin analogs.

#### Box 2: Use of other glucose-lowering drugs (based on consensus) {#Sec17}

All combination use is subject to local registration rules.Metformin should always be continued unless it is poorly tolerated or contraindicated (e.g., patient with renal dysfunction).Consider maintaining sulfonylureas with once-daily premix insulin. However, they should not be given at the same time of day as the premix insulin dose. Discontinue sulfonylureas once patients intensify to twice-daily premix insulin.Dipeptidyl peptidase-4 inhibitors/sodium-glucose cotransporter-2 inhibitors/alpha-glucosidase inhibitors can be continued together with insulin.Thiazolidinediones: combining these agents with insulin may exacerbate edema.Glucagon-like peptide-1 agonists may be insulin sparing and can be used.Consider lowering the dose of the non-insulin drug, other than metformin, at insulin initiation.

Intensifying Insulin Therapy to Premix Insulin Analogs BID in Primary Care {#Sec18}
--------------------------------------------------------------------------

This guidance covers intensification from premix insulin analogs OD or basal insulin only to premix insulin analogs BID. Other choices of intensification regimen are not covered here. For a review of the options for a second-line insulin regimen, see Barnett and colleagues \[[@CR40]\].

### When to Intensify {#Sec19}

Intensification of insulin therapy is as important as initiation. Regular review with appropriate dose adjustment is critical, to ensure that the patient does not continue on their initiation regimen if glycemic control is suboptimal. Intensification is required if the individual's HbA1c level remains above the individualized target for 3--6 months without any obvious reversible reason such as a steroid course or dietary non-compliance. Insulin should also be intensified if 2-h postprandial blood glucose values are above 10 mmol/L (180 mg/dL) and there is a difference (postmeal minus premeal) of ≥3 mmol/L (≥54 mg/dL), or when the maximum dose of 40--50 units is reached on premix insulin analog OD.

### Practical Guidance for Switching {#Sec20}

Practical guidance already exists for intensifying from basal insulin only or premix insulin analog OD to premix insulin analog BID \[[@CR41]\]. "[Box 3](#Sec21){ref-type="sec"}" and Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} have been adapted from this reference. For titration and monitoring when intensifying to premix insulin analog BID, refer to the guidance above on initiation ("[Box 1](#Sec15){ref-type="sec"}").Fig. 2A simple algorithm for switching from basal insulin therapy OD or BID (analog or human) to BID premix insulin analog. Modified from \[[@CR41]\]. *BID* twice daily, *FPG* fasting plasma glucose, *OD* once dailyFig. 3A simple algorithm for intensifying premix insulin analog therapy from OD to BID. Modified from \[[@CR41]\]. ^a^The evening meal is given as an example. Breakfast injections may also be suitable, in which case the pre-evening meal blood glucose should be monitored. ^b^Split the OD dose 50/50 breakfast and dinner. *BID* twice daily, *FPG* fasting plasma glucose, *OD* once daily

#### Box 3: Practical guidance for switching from basal insulin \[once daily (OD) or twice daily (BID)\], or from premix insulin analog OD, to premix insulin analog BID (based on consensus). Modified from \[41\]. {#Sec21}

From basal: 1:1 total dose switch to premix insulin analog. Split the dose 50/50 breakfast and dinner.From premix insulin analog OD: split the OD dose 50/50 breakfast and dinner.Administer premix insulin analog immediately before or soon after the start of a meal.Titrate the dose preferably once or twice a week (see "[Box 1](#Sec15){ref-type="sec"}").Adjust the evening meal dose first, followed by the breakfast dose.

As mentioned in "[Box 3](#Sec21){ref-type="sec"}", the total dose will usually be split 50/50 pre-breakfast and pre-dinner. However, this pattern may need to be varied in patients who eat light breakfasts or a main meal at lunch \[[@CR42]\].

If sulfonylureas have not already been discontinued, stop them when intensifying to a premix insulin analog BID. Also, take into consideration patient preference with respect to factors such as cost and pill load when deciding to cease other non-insulin glucose-lowering drugs.

If the patient is switching from an analog basal-only regimen, remember to educate them on the need to resuspend the protaminated insulin and the need to administer insulin with a meal.

### Further Intensification for Patients Already on Premix Insulin Analog BID {#Sec22}

Use of premix insulin analogs TID may be needed owing to poor control, but this regimen is used much less often than premix insulin analogs OD or BID. In the panel members' experience, the move from two to three injections daily can represent a larger barrier to patients than the move from one to two injections; patients must also be willing to undertake sufficient self-testing. If control is not satisfactory using a premix insulin analog BID, consider referring the patient to a specialist; otherwise, refer to the existing practical guidance for intensification \[[@CR41]\].

The ratio of short- to intermediate-acting insulin in both BIAsp 30 and lispro mix 25 will be appropriate for most patients. Different ratio premixes, such as 50% soluble rapid-acting insulin/50% protaminated insulin, are also available and can be useful for patients with specific needs (e.g., patients with very high PPG values or problems with hypoglycemia). For information on intensifying to higher ratio premix insulin analogs, refer to the published guidance \[[@CR43]\].

Switching from Basal--Bolus to Premix Insulin Analog Therapy in Primary Care {#Sec23}
----------------------------------------------------------------------------

### Practical Guidance: Chronic Treatment Failure {#Sec24}

Not all patients achieve successful glycemic control with long-term basal--bolus therapy. The reasons for this are many and, with further education, the regimen may prove to be appropriate. For others, switching to a premix insulin analog may be the right decision. For example, some patients are unwilling or unable to deal with complexity, or they may have tried a basal--bolus regimen but their circumstances may have changed. Others may find carbohydrate counting, dose adjustment, or the required degree of monitoring too difficult, or be unable to handle two different insulin delivery devices.

To date, there is limited published evidence concerning this change, although all practicing endocrinologists will have experience in this situation. Rather than suggesting a specific HbA1c cutoff for switching regimens, we suggest a switch to premix insulin analogs in patients who are clearly unable or unwilling to use basal--bolus therapy, or whose HbA1c has consistently remained above target despite using a basal--bolus regimen while having access to proper training and adequate information.

The default switch is to premix insulin analog BID, not TID, and the titration guidance shown in "[Box 4](#Sec25){ref-type="sec"}" is our suggested approach. If the patient is transferring from an analog basal--bolus regimen, education concerning the need to resuspend the protaminated insulin is important.

#### Box 4: Titration algorithm for switching from basal--bolus to premix insulin analog (based on consensus) {#Sec25}

General guidance: as always, titration must be tailored to the individual patient.These guidelines do not override clinical judgment and knowledge.Reduce total daily dose of all insulin by 20--30%.Then split this value 50/50 to give you the starting dose of premix insulin analog at breakfast and evening meal.Unusual meal patterns may lead you to reconsider the initial dose ratio.Titrate the dose preferably once or twice a week (see "[Box 1](#Sec15){ref-type="sec"}"). Adjust the evening meal dose first, followed by the breakfast dose.Safety is key: go slowly.

### Practical Guidance: Patients Discharged from Hospital {#Sec26}

Some hospitalized patients may have been placed on a basal--bolus regimen to provide a flexibility of management that is not required following discharge. Under these circumstances, switching to an alternate premix insulin regimen would be appropriate.

In such patients, it is important to be conservative, and insulin requirements may change dramatically from those required in hospital. Discharge planning is vital and expert input is desirable. For titration guidelines, see "[Box 4](#Sec25){ref-type="sec"}".

Conclusions {#Sec27}
===========

The purpose of this document is to provide practical and simplified guidance on the use of premix insulin analogs for insulin initiation and intensification in patients with T2D.

A review of published studies clearly demonstrates that proper use of any insulin regimen will result in a reduction in HbA1c, but that the greater the improvement in glycemic control, the greater the risk of side effects. Thus, individual patient factors and preferences become more important. As such, the choice of insulin regimen should be individualized to the patient, in the same way that glycemic targets are now individualized.

A figure is provided to help clinicians choose between premix insulin analogs or basal insulin for insulin initiation (Fig. [1](#Fig1){ref-type="fig"}). Key to making this choice is the need to bear in mind the patient's ability to cope with either a premix insulin analog or basal--bolus regimen when intensification of therapy is needed.

Guidance is provided on dosing, titration, the concomitant use of non-insulin glucose-lowering drugs, and other practical issues in both initiation and intensification. A titration algorithm is provided for the special case of switching from basal--bolus to premix insulin analog therapy ("[Box 4](#Sec25){ref-type="sec"}"). In all situations, safety is key and insulin should be titrated slowly.

The expert panel hopes that these recommendations, and in particular the specific dose values and targets, will prove a useful resource for all clinicians as they seek to provide optimal care for their patients with T2D.
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If HbA1c is above a certain point \[we suggest ≥8.5% (≥70 mmol/mol)\], it is also possible to initiate therapy with 6 units BID.
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